TransMedics Group, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2025: 21.88%

TransMedics Group, Inc. Return on Equity (ROE) is 21.88% for the Trailing 12 Months (TTM) ending March 31, 2025, a -404.99% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • TransMedics Group, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2024 was -7.18%, a -60.79% change year over year.
  • TransMedics Group, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2023 was -18.30%, a -71.17% change year over year.
  • TransMedics Group, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2022 was -63.48%, a 142.41% change year over year.
  • TransMedics Group, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2021 was -26.18%, a -56.49% change year over year.
Key Data
Date Return on Equity (ROE) Return on Assets (ROA) Revenue Per Share Free Cash Flow Per Share